CRSP - CRISPR Therapeutics AG

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
2.96B
Enterprise Value 3
2.22B
Trailing P/E
N/A
Forward P/E 1
-11.23
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
13.91
Price/Book (mrq)
5.00
Enterprise Value/Revenue 3
10.45
Enterprise Value/EBITDA 6
-424.68

Trading Information

Stock Price History

Beta (3Y Monthly) 3.12
52-Week Change 346.46%
S&P500 52-Week Change 314.27%
52 Week High 356.12
52 Week Low 322.22
50-Day Moving Average 342.71
200-Day Moving Average 344.37

Share Statistics

Avg Vol (3 month) 3495.19k
Avg Vol (10 day) 3591.43k
Shares Outstanding 555.2M
Float 32.72M
% Held by Insiders 141.38%
% Held by Institutions 144.50%
Shares Short (Oct 31, 2019) 45.29M
Short Ratio (Oct 31, 2019) 48.05
Short % of Float (Oct 31, 2019) 416.68%
Short % of Shares Outstanding (Oct 31, 2019) 49.57%
Shares Short (prior month Sep 30, 2019) 44.88M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Sep 30, 2019

Profitability

Profit Margin -5.30%
Operating Margin (ttm)-4.45%

Management Effectiveness

Return on Assets (ttm)-0.95%
Return on Equity (ttm)-2.23%

Income Statement

Revenue (ttm)212.69M
Revenue Per Share (ttm)4.01
Quarterly Revenue Growth (yoy)37,542.60%
Gross Profit (ttm)-110.65M
EBITDA -5.23M
Net Income Avi to Common (ttm)-11.27M
Diluted EPS (ttm)-0.22
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)629.72M
Total Cash Per Share (mrq)11.41
Total Debt (mrq)41.63M
Total Debt/Equity (mrq)7.03
Current Ratio (mrq)8.32
Book Value Per Share (mrq)10.72

Cash Flow Statement

Operating Cash Flow (ttm)24.93M
Levered Free Cash Flow (ttm)54.55M